Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
- Conditions
- HIV Infections
- Registration Number
- NCT00097799
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- Not specified
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (115)
1182.70.127 Health Services Center, Inc.
🇺🇸Anniston, Alabama, United States
1182.70.006 Spectrum Medical Group
🇺🇸Phoenix, Arizona, United States
1182.70.016 Health for Life Clinic
🇺🇸Little Rock, Arkansas, United States
1182.70.065
🇺🇸Anaheim, California, United States
1182.70.246
🇺🇸Baldwin Park, California, United States
1182.70.043
🇺🇸Fountain Valley, California, United States
1182.70.092
🇺🇸Fresno, California, United States
1182.70.057
🇺🇸Glendale, California, United States
1182.70.064
🇺🇸Harbor City, California, United States
1182.70.079
🇺🇸Long Beach, California, United States
Scroll for more (105 remaining)1182.70.127 Health Services Center, Inc.🇺🇸Anniston, Alabama, United States